LIGAND Pharmaceuticals director Zimmermann Martine sold 1,200 shares at $285 per share. The transaction represented about 23.5% of the director’s prior holding, while the reported post-sale balance was 3,897 shares, giving investors the disclosed scale and remaining ownership position.

Key Highlights

  • The transaction was recorded on 10 September 2026 under code S, denoting an open-market sale.
  • Zimmermann Martine’s reported holding stood at 3,897 shares after the transaction.
  • Zimmermann Martine sold 1,200 LIGAND Pharmaceuticals shares at $285 per share on 10 September 2026.

LIGAND PHARMACEUTICALS INC (NASDAQ: LGND) director Zimmermann Martine sold 1,200 shares at $285 per share.

Transaction Coded as Open-Market Sale

The transaction date was 10 September 2026. The reported sale relates directly to Zimmermann Martine’s holdings in LIGAND.

Director’s Post-Transaction Holding

Zimmermann Martine’s reported position after the transaction was 3,897 shares. The sale represented about 23.5% of the director’s prior shareholding. The two figures use different reference points: 3,897 shares describes the balance after the trade, while 23.5% measures the transaction against the earlier holding.